Kyntra Bio
KYNB
194 hedge funds and large institutions have $2.73B invested in Kyntra Bio in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 78 increasing their positions, 50 reducing their positions, and 20 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 50
45% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 20
21% more capital invested
Capital invested by funds: $2.25B → $2.73B (+$474M)
4% more funds holding
Funds holding: 187 → 194 (+7)
0.08% more ownership
Funds ownership: 2.94% → 3.02% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
36% less call options, than puts
Call options by funds: $18.7M | Put options by funds: $29.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$76.7M |
| 2 |
BlackRock
New York
|
+$34.6M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$19.8M |
| 4 |
Primecap Management
Pasadena,
California
|
+$17.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$126M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$30.7M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$12M |
| 4 |
AG
Artal Group
Luxembourg
|
-$7.43M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.31M |
KYNB Hedge Fund Activity: Q2 2020 in Review
194 of the 4,887 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2020, worth a combined $2.73B — up 21% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new KYNB positions and 20 closed out — a net gain of 9 holders — while 78 added to existing stakes and 50 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $76.7M. The largest seller was Fidelity Investments, cutting an estimated $126M.
- 194 institutional investors held Kyntra Bio (KYNB) as of Q2 2020, up from 187 in Q1 2020.
- Funds reported $2.73B of Kyntra Bio stock for Q2 2020, up 21% quarter-over-quarter.
- 29 funds opened new Kyntra Bio positions in Q2 2020 and 20 closed out, a net change of +9 holders.
- The largest Kyntra Bio buyer in Q2 2020 was T. Rowe Price Associates, an estimated $76.7M added.
- The largest Kyntra Bio seller in Q2 2020 was Fidelity Investments, an estimated $126M sold.
Based on aggregated 13F filings for Q2 2020.